Ahmedabad-based drug maker Torrent Pharmaceuticals Ltd has signed a share purchase agreement to acquire an additional 2.41% stake in J.B. Chemicals & Pharmaceuticals Ltd from employees for a total cash consideration...
Torrent Pharma set to finalise JB Chemicals buyout in 15-18 months
Ahmedabad-based drug maker Torrent Pharmaceuticals will complete its acquisition of JB Chemicals & Pharmaceuticals in the next 15-18 months subject to key regulatory approvals, a top company executive said in an...
AbbVie to buy Capstan for up to $2.1 billion in immunology push
AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases...
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a...
Torrent Pharma closes in on JB Chem likely for $2.4 bn buyout, eyes $1.6 billion financing
Torrent Pharma is in advanced discussions with private equity group KKR to buy JB Chemicals and Pharmaceuticals, almost 10 months after their initial discussions fell through, said multiple people aware. KKR the...
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion
US-based multinational pharmaceutical giant Eli Lilly & Co., on Tuesday, 17 June 2025, announced its plans to acquire gene-editing biotech firm Verve Therapeutics Inc. for $1.3 billion as the big pharma company eyes...
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb (BMY.N) has agreed to pay up to $11.1 billion to partner with Germany’s BioNTech and develop the latter’s next-generation cancer immunotherapy, which could take on rival Merck &...
Sun Pharma’s Checkpoint buy: Why it’s a strategic fit in the new SPIL focus
India’s largest drug maker, Sun Pharmaceutical Industries, has completed its acquisition of US-based Checkpoint Therapeutics for approximately $355 million. This strategic move significantly strengthens Sun Pharma’s...
Sanofi finds M&A fix for its multiple itches
LONDON, June 2 (Reuters Breakingviews) – Sanofi is one European giant that’s still focused on the United States. The $123 billion French drugmaker will pay up to $9.5 billion, for Blueprint Medicines, a U.S. group...
Bain Capital to buy PCI Pharma at $10 billion valuation, Bloomberg News reports
Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter. The buyout firm is in discussions...
TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India
TPG has agreed to acquire a 35% stake in drug containment firm SCHOTT Poonawalla from Serum Institute of India (SII). The decision was announced on Tuesday, and the acquisition is being led by TPG Growth—TPG’s middle...
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7...
